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Nimodipine is used throughout the world to improve outcome after aneurysmal subarachnoid hemorrhage 
(aSAH).1 Its use, however, is limited by systemic hypotension 
that occurs in ≤56% of patients.2 Plasma concentrations 
can exceed those associated with hypotension, yet cerebro-
spinal fluid (CSF) concentrations remain below the optimal 
Background and Purpose—We conducted a randomized, open-label, phase 1/2a, dose-escalation study of intraventricular 
sustained-release nimodipine (EG-1962) to determine safety, tolerability, pharmacokinetics, and clinical effects in 
aneurysmal subarachnoid hemorrhage.
Methods—Subjects with aneurysmal subarachnoid hemorrhage repaired by clipping or coiling were randomized to EG-
1962 or enteral nimodipine. Subjects were World Federation of Neurological Surgeons grade 2 to 4 and had an external 
ventricular drain. Cohorts of 12 subjects received 100 to 1200 mg EG-1962 (9 per cohort) or enteral nimodipine (3 per 
cohort). The primary objective was to determine the maximum tolerated dose.
Results—Fifty-four subjects in North America were randomized to EG-1962, and 18 subjects were randomized to enteral 
nimodipine. The maximum tolerated dose was 800 mg. One serious adverse event related to EG-1962 (400 mg) and 2 EG-
1962 dose-limiting toxicities were without clinical sequelae. There was no EG-1962-related hypotension compared with 
17% (3/18) with enteral nimodipine. Favorable outcome at 90 days on the extended Glasgow outcome scale occurred in 
27/45 (60%, 95% confidence interval 46%–74%) EG-1962 subjects (5/9 with 100, 6/9 with 200, 7/9 with 400, 4/9 with 600, 
and 5/9 with 800 mg) and 5/18 (28%, 95% confidence interval 7%–48%, relative risk reduction of unfavorable outcome; 
1.45, 95% confidence interval 1.04–2.03; P=0.027) enteral nimodipine subjects. EG-1962 reduced delayed cerebral ischemia 
(14/45 [31%] EG-1962 versus 11/18 [61%] enteral nimodipine) and rescue therapy (11/45 [24%] versus 10/18 [56%]).
Conclusions—EG-1962 was safe and tolerable to 800 mg, and in this, aneurysmal subarachnoid hemorrhage population was 
associated with reduced delayed cerebral ischemia and rescue therapy. Overall, the rate of favorable clinical outcome was 
greater in the EG-1962-treated group.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01893190.   
(Stroke. 2017;48:145-151. DOI: 10.1161/STROKEAHA.116.014250.)
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therapeutic threshold.3,4 Hypotension is deleterious to patients 
with aSAH because it lowers cerebral blood flow and cerebral 
perfusion pressure and worsens delayed cerebral ischemia 
(DCI).5
We hypothesized that EG-1962 (nimodipine in a biodegrad-
able polymer suspended in hyaluronic acid administered as 
one intraventricular injection that releases nimodipine into the 
subarachnoid space for at least 21 days) would increase effi-
cacy and reduce systemic side effects compared with enteral 
nimodipine.6–8 We performed a randomized, controlled, dose-
escalation study to determine the safety, maximum toler-
able dose (MTD), pharmacokinetics, and clinical effects of 
EG-1962 in humans (NEWTON [Nimodipine Microparticles 
to Enhance Recovery While Reducing Toxicity After 
Subarachnoid Hemorrhage).7
Methods
Study Design and Subjects
Subjects were randomized at 20 neurosurgical centers in the United 
States and Canada (online-only Data Supplement). The protocol 
was written by the authors, and the study was approved by insti-
tutional review boards. The protocol and written informed consent 
procedure are published (http://www.clinicaltrials.gov. Unique 
identifier: NCT01893190).7 Key inclusion criteria were World 
Federation of Neurological Surgeons (WFNS) grade 2 to 4 subjects 
with an external ventricular drain (EVD) inserted as standard of 
care and a ruptured aneurysm repaired by clipping or coiling. After 
the first cohort was entered, the inclusion criteria were amended to 
increase the time from aSAH to study drug administration from 48 
to 60 hours to facilitate recruitment. The rationale was that in the 
first cohort, plasma pharmacokinetics showed a rapid increase in 
plasma nimodipine concentrations within 24 hours of administra-
tion of EG-1962. Nimodipine is approved to reduce DCI after SAH, 
and this occurs 3 to 14 days after SAH. The approval says to start 
nimodipine within 4 days of SAH. Therefore, we thought it would 
be safe to increase the inclusion time to 60 hours. There was no 
reason to think this would affect the assessment of the MTD. The 
second cohort was administered EG-1962, 200 mg.
The study was to include a dose-escalation period followed by a 
treatment period (Figure I in the online-only Data Supplement). The 
primary objective of the dose-escalation period was to determine the 
MTD of EG-1962 and of the treatment period to further determine 
the safety and tolerability of the selected dose of EG-1962 compared 
with enteral nimodipine. The treatment period was not conducted 
based on the following. There were only 2 dose-limiting toxicities 
(DLT) spread among 2 different dose groups, and the number of seri-
ous adverse events (SAE) among the dose groups did not seem to 
have any dependence on dose. Favorable responses did not exhibit 
a dose–response, in that the rate was already high at the 100 mg 
dose. The dose–response relationship was assessed by visual inspec-
tion of the outcomes by cohort and by e-max and logistic regression 
models adjusting for WFNS grade and age (dichotomized). Finally, 
there was a strong dose–response seen in some key pharmacokinetic 
parameters. The secondary objective was to measure plasma and 
CSF concentrations of nimodipine; these will be reported separately. 
Exploratory end points were angiographic vasospasm, DCI, cerebral 
infarction caused by DCI, rescue therapy, and clinical outcomes at 
days 30 and 90.7,9 Definitions of these events are published and fol-
lowed recommendations of a multidisciplinary consensus statement.9 
Health economic outcomes will be reported separately. A computed 
tomography scan was obtained at day 30. The extended Glasgow 
outcome score (GOSE), Montreal cognitive assessment, modified 
Rankin scale, Barthel index, and telephone interview of cognitive 
status were conducted by study coordinators, who were trained in 
administering the outcome measures, at days 30 and 90 and National 
Institutes of Health stroke scale at days 7, 14, and 90.10–15
In part 1, cohorts of subjects were randomized (by biased coin 
method) to receive either EG-1962 or enteral nimodipine with a 
minimization procedure based on WFNS grade.16 WFNS grade was 
chosen for this because it is the most powerful prognostic factor for 
outcome after aSAH.17,18 Randomization was computer generated 
by an independent company using interactive response technology. 
Allocation concealment was maintained because study centers did 
not know what other subjects entered into a given cohort had received. 
Up to 6 dose-level cohorts of EG-1962 were to be assessed during 
the dose-escalation part. Each dose-level cohort enrolled 12 subjects 
in a 3:1 (EG-1962:enteral nimodipine) ratio. The starting dose of 
EG-1962 was 100 mg, and the maximum dose was 1200 mg. These 
doses were based on preclinical studies and were allowed under an 
Investigational New Drug Application to the United States Food 
and Drug Administration and a Clinical Trial Application to Health 
Canada.8 EG-1962 (100 mg nimodipine/mL [Evonik Industries, 
Birmingham, AL] suspended in hyaluronic acid [Fidia Farmaceutici 
SPA, Abano Terme, Italy]) was administered as one intraventricular 
injection. After reconstitution in the pharmacy, it was transported to 
the subject’s bedside and remixed. Up to 5 mL CSF was aspirated from 
the EVD under sterile conditions. The syringe containing EG-1962 
was then administered and flushed through the EVD with sterile, 
preservative-free 0.9% NaCl. It was recommended that the EVD 
remain closed and that CSF be drained only if clinically indicated. 
Once randomized, subjects assigned to EG-1962 no longer received 
enteral nimodipine. An independent data safety monitoring commit-
tee reviewed the safety, occurrence of predefined DLT, stopping rules, 
plasma nimodipine pharmacokinetics, and tolerability data up to day 
14 for each cohort. A decision was then made to increase the dose 
by some amount to determine that the MTD was reached or to enter 
another cohort with a lower dose. With the exception of the doses for 
cohort 1 (100 mg) and cohort 6 (1200 mg), the EG-1962 dose to be 
administered in cohorts 2, 3, 4, and 5 could be modified based on the 
data safety monitoring committee recommendation. Safety and DLT 
information was reported by the investigators up until day 90. The 
MTD was reached if ≥3 subjects receiving EG-1962 had a DLT or if 
the 1200 mg dose was reached. Management of subjects, DLT, and 
adverse events was outlined in the protocol and followed guidelines 
for management of aSAH.7,19,20
Statistical Analysis
Cohort size estimates were based on the analysis of published aSAH 
data and supported a dose-escalation scheme with 9 EG-1962 and 
3 enteral nimodipine subjects per cohort.21 The safety data set (all 
subjects randomized who received EG-1962 or enteral nimodipine 
and were assessed for safety at least once) included 72 subjects. 
Exploratory outcomes were based on a modified intent to treat (all 
subjects who were included in the safety analysis set and who had 
GOSE assessments at day 30 or 90). The modified intent to treat set 
excluded 1200 mg EG-1962 subjects because this dose was above the 
MTD. Only 3 subjects received the full dose, and some also received 
enteral nimodipine, which renders outcomes uninterpretable.
Demographics and safety data are reported as descriptive statistics 
(means, standard deviation). The first exploratory end point was the 
GOSE, analyzed as a dichotomous outcome (favorable outcome 6–8 
and unfavorable outcome 1–5). This cut point was based on analysis 
of existing data.7 The GOSE was compared between subjects in all 
cohorts combined randomized to enteral nimodipine and those ran-
domized to each of the EG-1962 dose groups and to the combined 
EG-1962 group. The prespecified analysis used Fisher exact test and 
the Cochran Mantel Haenszel test adjusted by WFNS grade (dichoto-
mized as 2 versus 3+4) and age (dichotomized as <60 or ≥60) because 
these are important admission prognostic factors for outcome and to 
adjust for differences between cohorts in WFNS grade and age.17,21 
Exact 95% (2-sided) confidence intervals (CI) for proportions and 
approximate 95% CI were used for relative risk ratios. Missing day-
90 outcome was scored as the day-30 outcome.17 We assessed interac-
tions of study group with WFNS grade and age, though the power is 
limited by the small sample size. Analysis was in SAS (version 9.2) 
and STATA (version 14.0).
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Results
Nine hundred and ninety-eight patients were prescreened 
(Figure I in the online-only Data Supplement). Seventy-
two subjects completed the North American study between 
October 28, 2013, and July 31, 2015; 54 subjects were ran-
domized to EG-1962 and 18 to enteral nimodipine (Figure 1). 
Demographics and baseline characteristics were consistent 
with patients with aSAH (Table 1).
No safety concerns limited dose escalation to 1200 mg. 
The maximum tolerated dose was 800 mg; 1200 mg was 
not tolerable because of the injection volume. Two DLT 
were reported, one each in cohort 3 (400 mg) and cohort 5 
(800 mg). Both were elevated intracranial pressure (ICP). 
Elevated ICP was considered a DLT if ICP was >30 mm Hg 
compared with the ICP recorded just prior to the administra-
tion of EG-1962 within 24 hours after EG-1962 administra-
tion and lasting over 4 hours despite appropriate therapy. In 
one case, the increased ICP was not associated with neuro-
logical deterioration, and the subject had a day-90 GOSE 
of upper moderate disability (favorable outcome). In the 
second case, there was transient neurological deterioration 
starting 13.5 hours after administration of EG-1962. The 
subject had a GOSE of lower good recovery (favorable out-
come) at day 90.
There were 3 deaths (6%) in the EG-1962-treated subjects 
(2 in the 200 mg cohort and 1 in the 800 mg cohort) and 1 
death (6%) in the enteral nimodipine group (in the 1200 mg 
cohort). None of these deaths were considered by the investi-
gator to be related to study drug, and all were a consequence 
of the initial brain injury from the aSAH, rebleeding, and 
withdrawal of care.
Through and including cohort 6 (1200 mg), 30 of 54 (56%) 
subjects treated with EG-1962 and 13 of 18 (72%) subjects 
treated with enteral nimodipine were reported to have treat-
ment-emergent SAE (Table 2). Central nervous system events, 
including cerebral vasoconstriction, DCI, cerebral infarction, 
and intracranial hemorrhage, were all more frequent in the 
enteral nimodipine group (Table 2).
The overall incidence of study medication–related adverse 
events was similar between the EG-1962 (12 [22%] with 13 
events) and enteral nimodipine groups (4 [22%] with 4 events). 
Three of the 4 adverse events related to enteral nimodipine 
were hypotension. Favorable outcome occurred in 1 of 4 of 
these subjects. In the EG-1962 treatment group, 9 of 12 study 
medication–related adverse events were increased ICP within 
24 hours of administration of EG-1962. Two were EVD mal-
functions, and 1 was a possible transient allergic reaction 
with no clinical sequelae. Favorable outcome occurred in 9 
of 12 (75%) of these subjects. In the EG-1962-treated sub-
jects, 1 SAE was considered by the investigator to be related 
to EG-1962 (possible transient allergic reaction with no clini-
cal sequelae).
The occurrence of increased ICP was not dose related. The 
overall incidence of increased ICP was similar between the 
EG-1962 (16/54, 30%) and enteral nimodipine (7/18, 39%) 
groups as was the rate reported as SAE (7% and 6% for the 
EG-1962 and enteral nimodipine groups, respectively). In the 
EG-1962 group, 12/13 (92%) subjects with increased ICP had 
a favorable outcome on the GOSE compared with 2/7 (29%) 
subjects in the enteral nimodipine group. Thirteen of 54 (24%) 
subjects had increased ICP within 24 hours of administration 
of EG-1962; 10 (77%) subjects had a favorable outcome. 
Figure 1. Study profile.
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In the enteral nimodipine group, 3/18 (17%) subjects expe-
rienced increased ICP within 24 hours of randomization; 1 
(33%) had a favorable outcome. In the EG-1962-treated group, 
6/54 (11%) subjects experienced increased ICP after 24 hours; 
3 (50%) had a favorable outcome. In the enteral nimodipine 
group, 4/18 (22%) subjects experienced late increased ICP; 1 
(25%) had a favorable outcome.
There were 5 cases of CSF culture–positive ventriculitis/
meningitis in subjects treated with EG-1962 (5/54, 9%) and 
none in those treated with enteral nimodipine. There were 3 
in cohort 2 (200 mg EG-1962) and 2 in cohort 6 (1200 mg). 
None were considered related to EG-1962. The day-90 out-
comes were favorable in 2/3 (67%) subjects who received 200 
mg and in 2/2 (100%) subjects who received 1200 mg.
There was a higher incidence of hypotension reported in 
the enteral nimodipine group (6/18, 33%) than in the EG-1962 
group (3/54, 6%). In the enteral nimodipine group, 3 of 6 
events of hypotension were reported as related to treatment, 
whereas in the EG-1962 group, no hypotension was consid-
ered related. There were no other clinically important imbal-
ances in adverse events in other organ systems.
The percent of subjects from cohorts 1 to 5 who achieved a 
favorable clinical outcome was greater in the EG-1962 group 
(60%, 27/45; 95% CI 46%–74%) compared with that in the 
enteral nimodipine group (28%, 5/18; 95% CI 7%–48%, 
relative risk reduction of unfavorable outcome; 1.45, 95% CI 
1.04–2.03, P=0.027, not adjusted for multiplicity, Fisher exact 
test). In cohort 6, 67% of 3 subjects who received the full 1200 
Table 1. Subject Demographics
Variable
Enteral 
Nimodipine
EG-1962
100 mg 200 mg 400 mg 600 mg 800 mg 1200 mg All EG-1962
Age 56±10 (18) 64±9 (9) 54±10 (9) 49±14 (9) 56±12 (9) 52±11 (9) 54±11 (9) 55±12 (54)
Male 5 (28) 1 (11) 3 (33) 5 (56) 6 (67) 7 (78) 2 (22) 24 (44)
WFNS grade
  Grade 2 5 (28) 3 (33) 4 (44) 7 (78) 2 (22) 3 (33) 6 (67) 25 (46)
  Grade 3 2 (11) 2 (22) 0 1 (11) 0 2 (22) 0 5 (9)
  Grade 4 11 (61) 4 (44) 5 (56) 1 (11) 7 (78) 4 (44) 3 (33) 24 (44)
Modified Fisher scale*
  Grade 2 2 (11) 2 (22) 2 (22) 1 (11) 3 (33) 2 (22) 2 (22) 12 (24)
  Grade 3 5 (28) 2 (22) 1 (11) 3 (33) 0 3 (33) 2 (22) 11 (22)
  Grade 4 11 (61) 4 (44) 5 (56) 4 (44) 6 (67) 4 (44) 5 (56) 28 (55)
Aneurysm 
clipping
12 (67) 3 (33) 7 (78) 3 (33) 5 (56) 5 (56) 4 (44) 27 (50)
Values are means±standard error of the mean (n) or n (%). WFNS indicates World Federation of Neurological Surgeons.
*Fisher scale missing on 2 subjects (one in the 100 mg cohort and one in the 200 mg cohort); one subject in the 400 mg cohort had a score of 1.
Table 2.  Adverse Events
Event
Enteral 
Nimodipine
EG-1962
100 mg 200 mg 400 mg 600 mg 800 mg 1200 mg All EG-1962
Subjects with ≥1 treatment-emergent adverse 
event
18 (100) 9 (100) 9 (100) 9 (100) 9 (100) 9 (100) 9 (100) 54 (100)
Number of adverse events 5 (28) 1 (11) 3 (33) 5 (56) 6 (67) 7 (78) 2 (22) 24 (44)
  Suspected related to study drug 4 (22) 0 (0) 0 (0) 3 (33) 1 (11) 5 (56) 3 (33) 12 (22)
  Serious adverse events (including deaths) 13 (72) 5 (56) 5 (56) 6 (67) 3 (33) 6 (67) 5 (56) 30 (56)
  Hypotension related to study drug 3 (17) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
  Ventriculitis/meningitis 0 (0) 0 (0) 3 (33) 0 (0) 0 (0) 0 (0) 2 (22) 5 (9)
Cerebral vasoconstriction/delayed cerebral 
ischemia
11 (61) 5 (56) 2 (22) 4 (44) 2 (22) 2 (22) 5 (56) 20 (37)
Hydrocephalus 3 (17) 2 (22) 2 (22) 1 (11) 2 (22) 3 (33) 3 (33) 13 (24)
Intracranial pressure increased at any time 7 (40) 3 (33) 0 (0) 4 (44) 1 (11) 5 (56) 3 (33) 16 (31)
Any intracranial hemorrhage 3 (17) 0 (0) 1 (11) 1 (11) 1 (11) 0 (0) 0 (0) 3 (6)
Any cerebral infarction 3 (17) 3 (33) 1 (11) 0 (0) 0 (0) 1 (11) 0 (0) 5 (9)
Values are n (%).
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mg dose had favorable outcome. Furthermore, 29% (13/45) 
of subjects treated with EG-1962 had GOSE scores of upper 
good recovery, whereas 6% (1/18) of the subjects treated with 
standard-of-care enteral nimodipine achieved that result. All 
doses yielded higher rates of favorable outcomes compared 
with that of enteral nimodipine with no dose relationship 
apparent (Figure 2).
Favorable outcome for subjects treated with EG-1962 com-
pared with those treated with enteral nimodipine was more 
likely both for subjects with WFNS 2 (89% versus 40%) and for 
subjects with WFNS 4 (43% versus 27%; Table 3). Exploratory 
analysis of the NEWTON data confirmed existing literature 
that the most important prognostic factors for outcome were 
WFNS grade and age. There were few WFNS grade 3 subjects, 
and the most optimal grouping for WFNS grade was 2 versus 
3+4. Age was analyzed as a dichotomous variable, with the 
cut point selected based on prior prognostic modeling and at a 
point producing similar numbers of subjects in each category 
(<60 or ≥60 years old).17 The pooled relative risk reduction 
for favorable outcome for all EG-1962 subjects versus enteral 
nimodipine subjects, adjusting for WFNS grade and age, was 
1.84 (95% CI 0.88–3.85; Cochran Mantel Haenszel test). For 
each dose cohort of EG-1962 compared with enteral nimodip-
ine, controlling for WFNS grade and age, the relative risk 
reduction, adjusted for WFNS grade and age, was 1.46 (95% 
CI 0.97–2.20; Cochran Mantel Haenszel test). There were no 
interactions between treatment group and WFNS grade (2 ver-
sus 3+4) or age.
Treatment with EG-1962 at 200 mg or more was associated 
with less angiographic vasospasm/DCI, infarction because 
of DCI, and use of rescue therapy compared with enteral 
nimodipine (Figure 3). Subjects who did develop angio-
graphic vasospasm or DCI were more likely to have favorable 
outcome if they were treated with EG-1962 (53%) compared 
with enteral nimodipine (18%).
Discussion
Nimodipine was developed to reduce angiographic vasospasm 
after aSAH.22 At tolerable doses, there was minimal effect on 
angiographic vasospasm.3,4,23 Current theory is that multiple 
processes contribute to DCI and delayed infarction, including 
angiographic vasospasm, cortical spreading ischemia, micro-
thromboembolism, loss of autoregulation, and capillary transit 
time heterogeneity.24–27 Nimodipine may have improved outcome 
because it inhibits these deleterious processes, but at tolerable 
doses has only a small effect on the most widely measured pro-
cess (angiographic vasospasm). Evidence consistent with this 
is that at some doses, nimodipine and other dihydropyridines 
reduce angiographic vasospasm, cortical spreading ischemia, and 
microthromboembolism.6,28–30 Nimodipine may have improved 
outcome because it inhibits these deleterious processes, but at tol-
erable doses has only a small effect on the most widely measured 
process (angiographic vasospasm). NEWTON tested the hypoth-
esis that intracranial delivery of EG-1962, which achieved high 
and sustained CSF concentrations in preclinical studies, would 
increase efficacy without compromising safety.8
The NEWTON study objectives were met. The MTD was 
determined to be 800 mg because the volume of the 1200 
mg injection (12 mL) was not tolerable as a single injection. 
The only DLT were episodes of transient increased ICP after 
injection of EG-1962. One SAE, a possible allergic reaction 
that had no clinical sequelae, was reported as possibly related 
to EG-1962. EG-1962 was safe with the same or lower 
risk of central nervous system events such as hemorrhage 
compared with enteral nimodipine. As hypothesized, no 
EG-1962-related hypotension occurred, whereas 17% (3/18) 
of subjects in the enteral nimodipine group experienced dose-
limiting hypotension. Meningitis and ventriculitis were the 
only adverse events more common in the EG-1962 group 
(5/54, 9%). We attribute this in part to the protocol requesting 
repeated sampling of CSF for nimodipine pharmacokinetics. 
This infection rate is comparable to analysis of 33 studies 
with 9667 cases from the literature that found a pooled infec-
tion incidence of 8%.31 This study allowed for institutional 
practice to be followed for EVD insertion. There was no 
study-mandated protocol for EVD insertion. Future studies 
Figure 2. Outcome on the extended Glasgow outcome score 
(GOSE) at day 90. Numbers are number of subjects with favor-
able outcomes (GOSE of 6–8) for each cohort (n=9) and enteral 
nimodipine (n=18). For each dose cohort of EG-1962 compared 
with enteral nimodipine, controlling for World Federation of Neu-
rological Surgeons (WFNS) grade and age, the adjusted odds 
ratio was 1.17 (95% confidence interval [CI] 0.87–1.59; P=0.29).
Table 3. Extended Glasgow Outcome Scale by WFNS Grade
WFNS
Cohorts 1 to 5
EG-1962 Enteral Nimodipine
N Favorable Outcome N Favorable Outcome
2 19 17 (89) 5 2 (40)
3 5 1 (20) 2 0 (0)
4 21 9 (43) 11 3 (27)
3+4 26 10 (38) 13 3 (23)
Total 45 27 (60) 18 5 (28)
Values are n (%). The 30-day outcome was carried forwards for 3 subjects 
(200 mg cohort, WFNS grade 2, favorable outcome; 400 mg cohort, WFNS grade 
2, unfavorable outcome; 600 mg cohort, WFNS grade 2, favorable outcome 
[this subject also had favorable outcome at 120 days). WFNS indicates World 
Federation of Neurological Surgeons.
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of EG-1962 will mitigate the risk of infection by requiring 
adherence to protocols for EVD insertion and intraventricular 
injection and by not obtaining CSF samples unless clinically 
indicated.31,32
Treatment with EG-1962 was associated with improved 
outcome on the GOSE, an effect that was robust over differ-
ent WFNS grades (Table 3). Furthermore, EG-1962 subjects 
had reduction in angiographic vasospasm, DCI, and need 
for rescue therapy. Favorable response rates were greater 
than control at all doses, with no obvious dose relationship. 
The lack of dose–response is consistent with randomized 
trials of enteral nimodipine that showed similar outcomes 
with doses of 30 to 90 mg nimodipine every 4 hours for 
21 days.3,4,23 Furthermore, studies of drugs targeting central 
nervous system disorders frequently do not demonstrate 
strong dose–responses and have wide ranges of recom-
mended doses.
Limitations of this study include that the number of sub-
jects treated was small, it was unblinded, and we used a modi-
fied intent–to-treat analysis for the clinical outcome. There 
were differences between cohorts in numbers of subjects at 
baseline with different WFNS grades, which was anticipated 
and adjusted for in the statistical analysis. Finally, subjects 
randomized represent a select population of SAH patients. 
Whether similar results could be obtained by administering 
EG-1962 by lumbar injection or whether an EVD could be 
indicated for the primary purpose of administering EG-1962 
cannot be determined at this time.
Summary
Intraventricular EG-1962 was safe and tolerable to 800 mg 
and, in this aSAH population, was associated with reduced 
DCI and use of rescue therapy. Overall, the rate of favorable 
outcome was greater in the EG-1962-treated group. A pivotal 
phase 3, double-blind, double-dummy, randomized clinical 
study of EG-1962 compared with enteral nimodipine has been 
started.
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